Ras oncogene point mutations in bladder cancer resistant to cisplatin.
Bladder tumors respond to cisplatin-based chemotherapy in 68% of cases, but only 30% will have a durable response. Recent studies have suggested that ras point mutations may produce cisplatin drug resistance in cell lines. To determine the role of ras point mutations in human tumors resistant to cisplatin, we evaluated ten tumors exposed to cisplatin and eight untreated bladder tumors for ras point mutations. Using polymerase chain reaction DNA amplification and allele-specific oligo-hybridization, we found that only one of the ten treated tumors and none of the untreated tumors harbored a ras point mutation. We conclude that ras point mutations occur infrequently in untreated bladder tumors and do not appear to correlate with cisplatin drug resistance in vivo.
Wood
D P
DP
Laboratory of Cancer Genetics, Sloan-Kettering Institute, New York.
Anderson
A E
AE
Fair
R
R
Chaganti
R S
RS
D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000235:genetics*; D002945:Cisplatin / Q000627:therapeutic use*; D004351:Drug Resistance / Q000235:genetics; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015345:Oligonucleotide Probes; D016133:Polymerase Chain Reaction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics*
D015345:Oligonucleotide Probes; D002945:Cisplatin